A recent study by the University of Turku and the University of Helsinki in Finland and the Finnish Social Insurance ...

Enrollment and dosing underway in Phase 3 clinical trial (the“MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML </p ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded ...

Thoughts of suicide was confirmed as a side effect of finasteride (Propecia, Proscar), the European Medicines Agency (EMA) ...

The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of ...

The initial POC results, presented April 26, 2025 at the Annual ELITE PED-GI Congress, show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave conditional marketing authorization for Oczyesa (octreotide) for the ...

(RTTNews) - argenx SE (ARGX) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission approval of VYVGART ...